Catalyst Wire Dossier Catalyst Wire Dossier

Fluticasone propionate-salmeterol 250/50 mcg inhalation powder

Fluticasone propionate; Salmeterol xinafoate · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Fluticasone propionate-salmeterol 250/50 mcg inhalation powder, covering 2011-05-20 to 2017-06-12. Get the full timeline:

Most recent: Clinical Trial Update: An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma [Phase 3]

See pricing